Alpelisib Market Poised for Strong Growth, Driven by Rising Cancer Incidences and FDA Approvals

Alpelisib Market Poised for Strong Growth, Driven by Rising Cancer Incidences and FDA Approvals

Alpelisib Market, marketed under the brand name Piqray, is a prescription medication used to treat cancer, particularly breast cancer and certain genetic mutations. The increasing incidence of cancer, particularly breast cancer, combined with the growing number of FDA drug approvals, is driving the expansion of the alpelisib market.

Download FREE Sample Report: https://www.nextmsc.com/alpelisib-market/request-sample

Market Overview

Alpelisib is a targeted therapy that works as a protein kinase inhibitor. It targets the p110-alpha isoform of the PI3K protein, which is instrumental in cell growth and survival. By blocking this protein, Alpelisib prevents the growth of cancer cells, including those in HER2-negative hormone-receptor-positive breast cancer. It is often used in combination with other therapies, such as fulvestrant, to treat postmenopausal women and men who have developed advanced breast cancer or have a PIK3CA gene mutation.

Beyond breast cancer, Alpelisib has applications in treating other cancers, including leukemia and thalassemia. It is also used to treat patients with PIK3CA-related overgrowth spectrum (PROS), a condition marked by abnormal growth of tissues and organs.

Market Dynamics and Drivers

The global alpelisib market is primarily driven by:

  1. Rising Cancer Incidence: The increasing number of cancer diagnoses, particularly breast cancer, is a significant factor driving the demand for Alpelisib. According to the American Cancer Society, in 2021, there were approximately 1.9 million new cancer cases and 608,570 cancer-related deaths in the United States alone. In addition, global breast cancer diagnoses are rising, with an estimated 2.3 million cases and 685,000 deaths in 2020, according to the National Library of Medicine.
  2. FDA Approvals: The growing number of FDA approvals for Alpelisib-based therapies is further fueling the market’s growth. In April 2022, the FDA approved Vijoice for treating patients aged 2 years and older with PIK3CA-related overgrowth spectrum (PROS). This has expanded the range of Alpelisib’s applications, driving adoption in both pediatric and adult populations.
  3. Breast Cancer Treatments: Alpelisib's effectiveness in combination with fulvestrant for hormone receptor-positive, HER2-negative breast cancer is particularly valuable, as it helps address the growing cases of advanced and metastatic breast cancer in postmenopausal women. The drug’s role in slowing or halting cancer progression in these populations is a significant market driver.
  4. Increased Awareness and Adoption: Rising awareness about cancer treatments and growing adoption of targeted therapies are fueling the market for Alpelisib. In addition, the growing awareness of menopausal symptoms and the lack of understanding of menopause treatments is leading to a higher demand for therapies like Alpelisib.

Market Challenges

While the market shows promising growth prospects, several factors may hinder the expansion of the Alpelisib market:

  • High Treatment Costs: The cost of Alpelisib remains a significant barrier to access in certain regions. This, combined with the high cost of ongoing cancer treatment, may deter widespread adoption, particularly in low- and middle-income countries.
  • Side Effects and Risks: Alpelisib has known side effects, including hyperglycemia (high blood sugar), which could limit its use in certain patient populations. These risks, along with the complexities of managing side effects, could pose challenges for patients and healthcare providers alike.
  • Raw Material Shortages: The availability of raw materials, such as triethylamine, is another challenge that could affect the production of Alpelisib, potentially limiting supply and driving up prices.

Despite these challenges, the market presents ample opportunities due to growing chemotherapy adoption, approvals of small-molecule injectables, and expanding uses for Alpelisib in oncology and beyond.

Inquiry Before Buying: https://www.nextmsc.com/alpelisib-market/inquire-before-buying

Market Segmentation and Scope

The Alpelisib market is segmented based on:

  • Product Type: Piqray and Vijoice.
  • Application: Oncology (breast cancer, other cancers), Postmenopause, and others.
  • Distribution Channel: Drug stores, mail-order pharmacies, and online platforms.
  • Geography: North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Geographical Insights

  • North America: North America holds a dominant share of the Alpelisib market, owing to the high prevalence of breast cancer and increasing FDA approvals for Alpelisib-based therapies. In addition, the demand for targeted molecular treatments in oncology is higher in this region.
  • Asia-Pacific: The Asia-Pacific region is expected to see steady growth in the Alpelisib market, primarily driven by increasing approvals of Alpelisib in countries like the Philippines and India. In July 2022, the Philippine Food and Drug Administration approved Alpelisib in combination with fulvestrant for treating advanced breast cancer in postmenopausal women. This, along with rising awareness and treatment adoption in countries like Japan, India, and China, is expected to drive market growth.

Competitive Landscape

Key players in the Alpelisib market include Novartis (the manufacturer of Piqray), Bristol Myers Squibb, and other pharmaceutical companies involved in oncology treatments. These companies are engaged in product launches, partnerships, and collaborations to enhance their market presence and expand the therapeutic applications of Alpelisib.

Key Benefits

  • The report provides quantitative and qualitative analysis of the Alpelisib market, including current and projected trends, to identify market opportunities.
  • Detailed analysis of drivers, restraints, and opportunities provides a comprehensive understanding of the market dynamics.
  • Competitive landscape analysis includes information on key players, their market shares, and strategic initiatives.
  • A SWOT analysis and Porter’s Five Forces model are used to analyze the competitive environment.
  • The value chain analysis offers insights into the roles of stakeholders involved in the Alpelisib market.

Conclusion

The Alpelisib market is on a strong growth path, fueled by increasing cancer incidences, rising FDA approvals, and expanding therapeutic applications. The market holds significant promise as the demand for targeted cancer therapies rises. However, challenges such as high costs and potential side effects must be addressed to ensure broader adoption. With continued innovation and awareness, Alpelisib is poised to play a crucial role in cancer treatment globally.

Also, Browse Related Reports:

For more information, please contact:

Next Move Strategy Consulting

E-Mail: info@nextmsc.com

Direct: +1-217-650-7991

Website: www.nextmsc.com

Follow Us: LinkedIn | Twitter | Facebook | Instagram | YouTube

 

About Next Move Strategy Consulting:

Next Move Strategy Consulting is a premier market research and management consulting firm that has been committed to provide strategically analysed well documented latest research reports to its clients. The research industry is flooded with many firms to choose from, what makes Next Move different from the rest is its top-quality research and the obsession of turning data into knowledge by dissecting every bit of it and providing fact-based research recommendation that is supported by information collected from over 500 million websites, paid databases, industry journals and one on one consultations with industry experts across a diverse range of industry sectors. The high-quality customized research reports with actionable insights and excellent end-to-end customer service help our clients to take critical business decisions that enables them to move beyond time and have competitive edge in the industry.

We have been servicing over 1000 customers globally that includes 90% of the Fortune 500 companies over a decade. Our analysts are constantly tracking various high growth markets and identifying hidden opportunities in each sector or the industry. We provide one of the industry’s best quality syndicates as well as custom research reports across 10 different industry verticals. We are committed to deliver high quality research solutions in accordance to your business needs. Our industry standard delivery solutions that range from the pre consultation to after-sales services, provide an excellent client experience and ensure right strategic decision making for businesses.

Back to blog